{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:59:44Z","timestamp":1789516784006,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":73,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["32003B_185,111"],"award-info":[{"award-number":["32003B_185,111"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Applied"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.nsa.2024.104060","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T02:19:51Z","timestamp":1710555591000},"page":"104060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Safety pharmacology of acute psilocybin administration in healthy participants"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2952-586X","authenticated-orcid":false,"given":"Isabelle","family":"Straumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1519","authenticated-orcid":false,"given":"Friederike","family":"Holze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-7945","authenticated-orcid":false,"given":"Anna M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9881-4693","authenticated-orcid":false,"given":"Laura","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nepomuk","family":"Halter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":false,"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nsa.2024.104060_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.nsa.2024.104060_bib2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.nsa.2024.104060_bib4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.nsa.2024.104060_bib5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/02698811221116926","article-title":"Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review","volume":"36","author":"Breeksema","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences","volume":"235","author":"Carbonaro","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nsa.2024.104060_bib9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.nsa.2024.104060_bib10","first-page":"217","article-title":"Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache","volume":"188","author":"Davenport","year":"2016","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.nsa.2024.104060_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatr."},{"issue":"Suppl. 2","key":"10.1016\/j.nsa.2024.104060_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.nsa.2024.104060_bib13","article-title":"Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy","author":"Dodd","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.nsa.2024.104060_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.nsa.2024.104060_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102997","article-title":"Making \"bad trips\" good: how users of psychedelics narratively transform challenging trips into valuable experiences","volume":"87","author":"Gashi","year":"2021","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.nsa.2024.104060_bib16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nsa.2024.104060_bib17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/7854_2016_457","article-title":"A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD","volume":"36","author":"Halpern","year":"2016","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.nsa.2024.104060_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.nsa.2024.104060_bib23","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","article-title":"Safety pharmacology of acute LSD administration in healthy subjects","volume":"239","author":"Holze","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2024.104060_bib25","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/jpet.111.188425","article-title":"Effects of the \u03b12-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers","volume":"340","author":"Hysek","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.nsa.2024.104060_bib28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek","year":"2014","journal-title":"Soc. Cognit. Affect Neurosci."},{"key":"10.1016\/j.nsa.2024.104060_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036476","article-title":"Duloxetine inhibits effects of MDMA (\"ecstasy\") in vitro and in humans in a randomized placebo-controlled laboratory study","volume":"7","author":"Hysek","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nsa.2024.104060_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2016","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.nsa.2024.104060_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","article-title":"Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers","volume":"123","author":"Johnson","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.nsa.2024.104060_bib33","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.nsa.2024.104060_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841648","article-title":"Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report","volume":"13","author":"McCulloch","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib36","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00213-022-06066-z","article-title":"Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants","volume":"239","author":"Muller","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.nsa.2024.104060_bib38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2022.2066650","article-title":"Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges","volume":"21","author":"Rossi","year":"2022","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.nsa.2024.104060_bib41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nsa.2024.104060_bib42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0269881120959604","article-title":"Acute subjective effects in LSD- and MDMA-assisted psychotherapy","volume":"35","author":"Schmid","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104060_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nsa.2024.104060_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.nsa.2024.104060_bib46","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0269881117691569","article-title":"Safety pharmacology of acute MDMA administration in healthy subjects","volume":"31","author":"Vizeli","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104060_bib47","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"E Clin. Med."},{"key":"10.1016\/j.nsa.2024.104060_bib48","series-title":"Die Beschwerden-Liste","author":"Zerssen","year":"1976"}],"container-title":["Neuroscience Applied"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277240852400125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277240852400125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T21:20:31Z","timestamp":1731360031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277240852400125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":48,"alternative-id":["S277240852400125X"],"URL":"https:\/\/doi.org\/10.1016\/j.nsa.2024.104060","relation":{},"ISSN":["2772-4085"],"issn-type":[{"value":"2772-4085","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety pharmacology of acute psilocybin administration in healthy participants","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Applied","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nsa.2024.104060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}],"article-number":"104060"}}